RNXT RenovoRx, Inc.
Financings ·
RenovoRx (Nasdaq: RNXT) sold 8,438,790 shares, pre-funded warrants and revenue milestone warrants to 15 investors, five of them insiders. The deal closed March 20, 2026.
RenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period.
RenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period.
RenovoRx sold 11,523,810 shares at $1.05, below the $1.46 last sale on February 6, 2025, with Titan Partners Group as sole bookrunner. The company held about $9.6 million in cash and short-term securities at September 30, 2024, and its prospectus carries a going concern paragraph.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $1.1 million | $43,000 |
| Research and development | $6.3 million | $6.0 million |
| Net income (loss) | -$11.2 million | -$8.8 million |
| Cash from operations | -$11.0 million | -$9.1 million |
| Cash and equivalents | $7.0 million | $7.2 million |
Our latest story on this, dated Feb 6, 2025: "RenovoRx prices 11,523,810-share offering at $1.05 for $12,100,001 in gross proceeds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 23, 2026: "RenovoRx closes private placement for about $10 million in gross proceeds". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Mar 31, 2025: "RenovoRx files NT 10-K, says annual report will be late". The story links the filing or release it is based on. Read the story.
RenovoRx, Inc. trades under the ticker RNXT on NASDAQ.
RenovoRx, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for RenovoRx, Inc. is 1574094. Its filings are on SEC EDGAR.
45,129,508 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-13.
Our directory records RenovoRx, Inc. under United States.
Our directory classifies RenovoRx, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for RenovoRx, Inc. is US75989R1077.
aibio.space lists RenovoRx, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$1.1 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
RenovoRx, Inc. reported a net loss of $11.2 million for the fiscal year ended Dec 31, 2025, and used $11.0 million of cash in operations, per its annual report to the SEC.
$6.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 424B5. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio